Loading...

LUPIN Lupin Ltd Major expansion or diversification plans Announcement

Lpn

LPN

Lupin Ltd

(LUPIN)

2025 Announcement

Strategic Alliance

Special Window for Transfer

ESG Rating Disclosure

New Product Launch

Exclusive Licensing Agreement

CSR rating recognition

FDA inspection clearance

New Product Launch

ESG Score Milestone

Regulatory Compliance

Q2 FY2026 Update

Oncology block expansion

FDA Inspection Success

Financial Results Published

Earnings Call Link

Investor Presentation

Q2 FY2026 Results

Quarterly Results

Financial Results Approved

FDA Report Received

Share Transfer Window

VITALYFE Launch

New Office Opening

Share Allotment

Earnings Call Scheduled

Board Meeting Notice

Phase 1 Data Presentation

Strategic Partnership Launch

New Facility Plans

Compliance Certificate

FDA Inspection Update

Liraglutide Launch

Rivaroxaban Launch

FDA Approval Received

Management Change

Acquisition Announcement

FDA Approval Received

ESG Rating Update

FDA Inspection Conducted

Share Transfer Notification

FDA Approval Received

ESG Rating Assigned

Postal Ballot Notice

Director Re-appointment

Bosentan Launch

Director Change

Q1 FY2026 Earnings

Glucagon Launch

Investor Meetings

Financial Results Published

Earnings Call Record

Investor Presentation

Q1 FY2026 Results

Stock Options Granted

Earnings Call Scheduled

FDA Approvals Granted

AGM Announcement

Annual General Meeting

GMP Certification Achieved

New Product Launch

AGM Announcement

ESG Rating Received

Compliance Confirmation

Partnership Agreement

License Agreement

Share Transfer Window

New Nasal Spray

FDA Approval Received

Healthcare Carve-Out

API R&D Division Transfer

Business Transfer Agreement

Prucalopride Launch

Share Allotment

Stock Options Granted

Supply Agreement Signed

FDA Approval Received

Stock Options Granted

Share Allotment

LNP7457 Presentation

Supply Agreement Signed

Loan Conversion

Investors Meet Transcript

Lupin-Honeywell Partnership

Director Changes

Annual Compliance Report

Financial Results Publication

Investor Meet Outcome

Investor Meeting

New Board Appointment

Management Changes

Auditor Appointment

Director Appointment

Tolvaptan Launch

FDA Approval Received

New Product Launch

Transfer Updates

Share Allotment

NABL Accreditation Achieved

FDA Inspection Report

Court Order Update

Compliance Certificate

Acquisition Announcement

Business Restructuring

API R&D Transfer

Management Retirement

Home Care Guide Launch

Nanomi Wins Award

Share Allotment

Sustainability Award

New Subsidiary Founded

New Product Launch

Sustainability Recognition

FDA Inspection Report

Earnings Call Transcript

Investor Meet Intimation

Postal Ballot Notice

CDP Leadership Rating

Financial Results Publication

Earnings Call Recording

Revised Results Announcement

Investor Presentation

Q3 FY2025 Results

Stock Option Scheme

New Subsidiary Launch

Business Restructuring

Management Changes

FDA Approval Granted

FDA Approval Received

Investor Meet Notification

GST Penalty Order

GST Penalty Notice

FDA Inspection Success

Share Allotment

Q3 FY25 Earnings

Stock Options Allotment

Acquisition Completed

FDA Inspection Report

Regulatory Compliance

Lupin Acquires Huminsulin

Share Allotment

Trademark Acquisition

FDA Approval Clarification

Investor Meeting

Analyst Meet Announcement

Earnings Call Transcript

Financial Results Published

Earnings Call Audio

Investor Presentation

Q2 FY25 Results

Earnings Call Scheduled

Management Change

First Generic Launch

Compliance Certificate

FDA Inspection Update

FDA Inspection Results

New Drug Agreement

Investor Meet Announcement

Equity Investment

GST Penalty Imposed

Tax Penalty Imposed

Q1 FY2025 Earnings

New Wholly Owned Subsidiary

Investor Presentation

Appointment of Officer

Retirement Announcement

Financial Results

Incorporation of Subsidiary

Show Cause Notices

Show Cause Notice

Shareholder Information

Divestiture Announcement

FDA Inspection Report

Certificate Submission

Business Transfer Completion

Judgement Announcement

FDA Inspection Report

Appointment of CEO

Change in Management

FDA Inspection Completion

LUPIN LTD. Agreement

Acquisition Update

Acquisition Completion

Settlement Agreement

US FDA Inspection

ISO Certifications

Appointment of Directors

Compliance Report Submission

Earnings Call Audio

Investor Presentation

Directorate Change

Financial Results

FDA Approval for Lupin

Penalty Order Received

Penalty Order Received

Penalty Imposed

Lupin Ltd Penalty Order

Lupin FDA Inspection Report

Earnings Call Update

FDA Inspection Completion

Certificate Compliance

Certificate Submission

Dr. Pathak Appointment

Management Change

Compliance Certificate

Income Tax Demand

LUPIN LTD. Disposals

GST Authority Order

Management Change

Completion of Transaction

Earnings Call Transcript

Earnings Call - Q3 FY24

Investor Presentation

LUPIN LTD. Q3 FY2024 Results

FDA Approval – Bromfenac Op...

Penalty Imposed

Digital Therapeutics Certif...

Earnings Call - Q3 FY24

Allotment of ESOP

FDA Approval for Generic Ul...

Aptivate Champion Run

Lupin Announces Aptivate Ch...

Certificate Submission

Acquisition of Established ...

US FDA Approval

Stock Options Granted

Expansion Plans

Conference Call Transcript

Partnership for Ranibizumab

Earnings Call - Q2 FY24

Allotment of ESOP

Investor Presentation

LUPIN LTD. Q2 FY2024 Results

Licensing Agreement

FDA Inspection Report Received

Business Transfer Agreement

Compliance Certificate

US FDA Approval

Launch of Patient Support P...

FDA Inspection Report Received

Asthma Educator Platform

Acquisition of Five Brands

Loss of Share Certificate

Transfer of API Manufacturi...

Collaboration for COPD Medi...

Acquisition of Medisol

Approval from US FDA

Asset Acquisitions

Stock options plan

New Product Launches

Equity, Debt, VC, Private E...

Primary Offerings

Financial Statements

Equity, VC Investment

New Product Launches

Financial Performance

Financial Statements

Equity, Debt, VC, Private E...

Equity, Debt, VC, Private E...

Debt-Equity Swaps

Equity Investment

New Product Launches

Merger of Equals

Inspection, Form-483 observ...

Equity Offerings

Financial Statements

New Product Launches

Approval Received

Generic drug approval

New Product Launches

New Product Launches

Regulatory Compliance

Product Expansion

Equity investment

Product Expansion

Earnings Call Transcript

Recording Posted Online

Financial Statements

Annual Secretarial Complian...

Financial Statements

Asset Acquisitions

Asset Acquisitions

External Links:

Data:

Lupin Ltd announced on October 9, 2025, a strategic partnership program to expand its long-acting injectable platform, PrecisionSphere, which has received U.S. FDA approval for its first product and aims to improve patient access to innovative treatments.

AI Assistant

Lupin Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.